Figure 2
From: EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia
Leukemia progression in xenograft models. (a) Flow cytometry gating strategy: hCD45 and mCD45. (b) Leukemia progression in blood, spleen and bone marrow of LK63 xenograft (n=3). (c) Spleen weight of LK63 xenograft (n=3 per time-point) compared with normal mouse (n=1 per time-point). (d) Histology of normal spleen. (e) Histology of spleen from LK63 xenograft. (f) Reduced spleen size in LK63/A3KD compared with LK63 xenografts (P<0.0001; n=4 LK63, n=5 LK63/A3KD). (g) Significant reduction in the spleen and bone marrow engraftment of LK63/A3KD xenograft compared with LK63 xenograft (P=0.02) (n=3 LK63, n=5 LK63/A3KD). (h) Leukemia progression in blood, spleen and bone marrow of Reh xenograft. (i) Spleen weight of Reh xenograft (n=3 per time-point) compared with normal mice (n=1 per time-point). Data presented as mean percentage±s.e.m. Unpaired t-test performed for statistical analyses.
